ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation

Karin Lövgren Bengtsson Isconova AB, Kungsgatan 109, SE-75318 Uppsala, Sweden

Bror Morein Department of Medical Sciences, Section of Virology, Uppsala University, Uppsala, Sweden

Albert DME Osterhaus Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands and ViroClinics Biosciences B.V., Rotterdam, The Netherlands

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

Karin Lövgren Bengtsson is CSO at Isconova AB and a minority shareholder. Bror Morein is a senior advisor to Isconova and is a shareholder of Isconova AB. Albert Osterhaus is CSO of ViroClinics Biosciences B.V. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation

Information for

Open access

Opportunities

Help and information

ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation

Financial & competing interests disclosure

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature